Citigroup Maintains Buy on Summit Therapeutics, Lowers Price Target to $42

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $43 to $42.